Paradigm Biocapital Advisors LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001855655

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 28 positions · Total reported value $5.34B · Top-10 concentration 75.2% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 66.7% · 7 new · 7 cut · 14 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +27.3% · vs SPY +12.5% · Prev Value $4.89B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Paradigm Biocapital Advisors LP disclosed 28 equity positions with a combined reported value of $5.34B. The filing implies a focused portfolio: its ten largest positions account for 75.2% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were RVMD ($1.19B), NUVL ($731.67M), EWTX ($415.05M). By sector, the heaviest allocations are Health Care 81.2%, Industrials 0.8%. Versus the prior quarter, allocation shifted toward Health Care (+14.3pp) and away from Other (-14.3pp).

Versus the prior quarter, Paradigm Biocapital Advisors LP opened 7 new positions, trimmed 7 and fully exited 14, a turnover rate of 66.7% of positions. The portfolio's overlap with the prior quarter was 50% of names.

The largest new positions opened in Q2 2026 were ALNY ($144.49M), MBX ($138.44M), JBIO ($63.49M).

Of the 14 positions fully exited versus the prior quarter, the largest were ACLX ($662.97M), CNTA ($141.96M), TERN ($116.85M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • ALNY ALNYLAM PHARMACEUTICALS · $144.49M
  • MBX MBX BIOSCIENCES INC · $138.44M
  • JBIO JADE BIOSCIENCES INC · $63.49M
  • ACHV ACHIEVE LIFE SCIENCES INC · $32.34M
  • MPLT MAPLIGHT THERAPEUTICS INC · $24.58M
  • KARD KARDIGAN INC · $21.46M
  • EDIT EDITAS MEDICINE INC · $18.10M

Fully Exited (vs previous quarter)

  • ACLX ARCELLX INC · prev qtr: $662.97M
  • CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $141.96M
  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $116.85M
  • CYTK CYTOKINETICS INC · prev qtr: $97.60M
  • ABVX ABIVAX SA · prev qtr: $86.01M
  • MAZE MAZE THERAPEUTICS INC · prev qtr: $81.92M
  • SRRK SCHOLAR ROCK HOLDING CORP · prev qtr: $60.27M
  • MIRM MIRUM PHARMACEUTICALS INC · prev qtr: $57.74M

Insider Transactions (Form 4)

Latest Paradigm Biocapital Advisors LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Paradigm Biocapital Advisors LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 28 positions worth $5.34B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-120338 (status: Approved), registered 2021-02-23
  • Regulatory AUM (Form ADV): $4.47B as of 2026-08-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 28 positions · $5.34B reported value (Q2 2026)
  • Top 10 holdings = 75.2% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 22.3%
  • Average position size: $190.73M

Sector Tilt

  • Health Care 81.2%
  • Industrials 0.8%
  • (classified holdings cover 82% of value)

Quarterly Activity

  • Q2 2026: 7 new, 12 added, 7 reduced, 14 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund seems to be actively seeking growth opportunities within the healthcare sector, with a preference for biotechnology and pharmaceutical companies. This is indicated by the addition of new holdings in this sector and the significant increase in weightings for several existing positions. 2. Key Moves: - Added: The fund increased its stake in Nuvalent (NUVL) by 11.3%, Edgewise Therapeutics (EWTX) by 38.7%, Genmab (GMAB) by 64.8%, Spire Therapeutics (SYRE) by 96.2%, Apogee Therapeutics (APGE) by 16.9%, Tango Therapeutics (TNGX) by 58.6%, and Belite Bio (BLTE) by 10.6%. - Reduced: The fund reduced its stake in Revolution Medicines (RVMD) by 4.4%, Orka Therapeutics (ORKA) by 7.6%, and Erasca Inc. (ERAS) by 8.1%. 3. Portfolio Structure: - Passive/Active: The fund appears to be more active in its approach, with significant additions and reductions in positions. - Sector Bias: The portfolio has a strong bias towards the healthcare sector, particularly biotechnology and pharmaceuticals. - Risk Appetite: The increased allocation to high-growth biotech companies suggests a higher risk appetite, as these companies often come with higher risk and volatility. 4. Per-Holding One-Liner: - RVMD: Developing novel cancer therapies - NUVL: Developing therapies for rare diseases - EWTX: Focused on developing therapies for orphan diseases - GMAB: Biopharmaceutical company specializing in cancer immunotherapy - SYRE: Developing novel therapies for neurological and psychiatric diseases - APGE: Focused on the development of novel treatments for cancer - ORKA: Developing therapies for rare and orphan diseases - TNGX: Focused on developing therapies for oncology - BLTE: Focused on the development of therapies for rare diseases - ERAS: Developing therapies for metabolic diseases 5. One-Sentence Style Summary: The Paradigm Biocapital Advisors LP rebalanced its portfolio in Q2 2026, increasing its exposure to high-growth biotech companies with a focus on innovative therapies for various diseases, indicating a proactive and sector-specific investment strategy.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 81.2%
Other 18.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 6.36M $1.19B 22.31%
22.31%
Reduce
2 5.92M $731.67M 13.70%
13.70%
Add
3 10.22M $415.05M 7.77%
7.77%
Add
4 13.13M $360.77M 6.75%
6.75%
Add
5 3.84M $340.98M 6.38%
6.38%
Add
6 1.58M $209.23M 3.92%
3.92%
Add
7 2.14M $204.09M 3.82%
3.82%
Reduce
8 6.36M $198.74M 3.72%
3.72%
Add
9 1.23M $189.84M 3.56%
3.56%
Add
10 9.55M $174.96M 3.28%
3.28%
Reduce
11 2.78M $174.70M 3.27%
3.27%
Add
12 480.00K $144.49M 2.71%
2.71%
New
13 1.33M $141.38M 2.65%
2.65%
Add
14 2.51M $138.44M 2.59%
2.59%
New
15 2.13M $123.69M 2.32%
2.32%
Reduce
16 6.72M $123.52M 2.31%
2.31%
Add
17 8.67M $108.47M 2.03%
2.03%
Add
18 2.86M $63.49M 1.19%
1.19%
New
19 1.83M $58.41M 1.09%
1.09%
Reduce
20 1.55M $42.70M 0.80%
0.80%
Add
21 2.89M $41.33M 0.77%
0.77%
Reduce
22 4.95M $32.34M 0.60%
0.60%
New
23 1.75M $32.22M 0.60%
0.60%
Hold
24 685.85K $24.58M 0.46%
0.46%
New
25 900.00K $21.46M 0.40%
0.40%
New
26 4.18M $19.44M 0.36%
0.36%
Reduce
27 5.59M $18.10M 0.34%
0.34%
New
28 4.00M $15.12M 0.28%
0.28%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 60% R 60% F1 60% (modelled on 2026-Q1; 6/10 hit)

Low-confidence forecast This fund replaces about 32% of its Top-10 each quarter and backtests at F1 71% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 71% · recall 71% · F1 71% · avg rank error 2.5 · Top-10 turnover 32%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% NUVL · ACLX · ARGX · IRON · VRDN · LEGN · OLMA · XENE · IMCR · CERE NUVL · ACLX · ARGX · IRON · CRNX · SRPT · IMCR · LEGN · ARVN · XENE
2024-Q2 60% 60% 60% NUVL · ACLX · ARGX · IRON · CRNX · SRPT · ARVN · IMCR · TARS · XENE NUVL · ARGX · ACLX · RVMD · SRPT · IRON · MRUS · CRNX · CERE · KURA
2024-Q3 70% 70% 70% NUVL · ARGX · RVMD · ACLX · SRPT · IRON · MRUS · CRNX · KURA · ASND NUVL · ARGX · RVMD · CRNX · MRUS · JANX · KURA · TARS · EWTX · IRON
2024-Q4 70% 70% 70% NUVL · RVMD · ARGX · MRUS · CRNX · JANX · KURA · TARS · EWTX · IRON NUVL · ACLX · ARGX · RVMD · JANX · TARS · EWTX · PCVX · ONC · CRNX
2025-Q1 70% 70% 70% NUVL · ACLX · ARGX · RVMD · JANX · TARS · PCVX · EWTX · ONC · MLTX NUVL · ACLX · RVMD · ONC · MRUS · TARS · JANX · CRNX · PCVX · IRON
2025-Q2 90% 90% 90% NUVL · ACLX · RVMD · ONC · MRUS · TARS · JANX · PCVX · CRNX · COGT NUVL · ACLX · MRUS · RVMD · TARS · PCVX · ONC · EWTX · COGT · JANX
2025-Q3 70% 70% 70% NUVL · ACLX · MRUS · RVMD · PCVX · TARS · EWTX · COGT · ONC · CRNX NUVL · ACLX · RVMD · TARS · PCVX · ABVX · GMAB · CRNX · XBI · EWTX
2025-Q4 80% 80% 80% NUVL · ACLX · RVMD · TARS · PCVX · ABVX · GMAB · EWTX · CRNX · XBI NUVL · RVMD · ACLX · GMAB · TARS · ABVX · OLMA · PCVX · XBI · CDTX
2026-Q1 70% 70% 70% RVMD · NUVL · ACLX · GMAB · TARS · XBI · PCVX · OLMA · ABVX · EWTX ACLX · RVMD · NUVL · PCVX · EWTX · GMAB · INSM · TARS · BLTE · ERAS
2026-Q2 ★ 60% 60% 60% ACLX · RVMD · NUVL · PCVX · GMAB · EWTX · INSM · TARS · BLTE · ERAS RVMD · NUVL · EWTX · GMAB · SYRE · APGE · ORKA · TNGX · BLTE · ERAS

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Paradigm Biocapital Advisors LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Paradigm Biocapital Advisors LP reported 28 equity positions worth $5.34B in aggregate; its largest disclosed positions were RVMD ($1.19B), NUVL ($731.67M), EWTX ($415.05M).

How large is Paradigm Biocapital Advisors LP's portfolio?

Paradigm Biocapital Advisors LP reported $5.34B of long equity holdings across 28 positions as of 2026-Q2. Top-10 holdings account for 75.2% of reported value.

What is Paradigm Biocapital Advisors LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/paradigm-biocapital-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →